Literature DB >> 24064020

Patient-driven assessment of disease activity in Behçet's syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet's Syndrome Activity Score.

Sedat Yilmaz1, Ismail Simsek, Muhammet Cinar, Hakan Erdem, Osman Kose, Yusuf Yazici, Salih Pay.   

Abstract

OBJECTIVES: The Behçet's Syndrome Activity Score (BSAS) is the first patient reported outcome measure developed to assess the global disease activity in patients with Behçet's syndrome (BS). We aimed to evaluate the reliability and validity of the Turkish version of BSAS for measuring disease activity in BS. We further investigated the performance of Routine Assessment of Patient Index Data (RAPID)3, a patient-reported index originally developed for rheumatoid arthritis, in BS patients.
METHODS: Patients seen consecutively at a tertiary Rheumatology Centre were requested to complete BSAS and multidimensional health assessment questionnaire (MDHAQ). Besides, all attending physicians filled the Behçet's Disease Current Activity Form (BDCAF). Descriptive statistics and Pearson correlation coefficients were calculated accordingly for the reliability and validity assessments of BSAS.
RESULTS: A total of 104 patients completed all three assessments. The test-retest reliability of BSAS has a good level (ICC=0.84, 95% CI [0.69-0.94]). The mean scores for BSAS, BDCAF and RAPID3 were 39±20.8, 3.2±1.4 and 9.2±5.6, respectively. BSAS was correlated with BDCAF moderately (r=0.587), while it was moderately correlated with RAPID3 (r=0.648). The correlation between the RAPID3 and BDCAF was moderate (r=0.403), but lower as compared to the correlations between the other instruments.
CONCLUSIONS: We found that the BSAS has modest correlation with BDCAF and is a reliable and valid patient reported measure of disease activity that can be used to assess patients with BS. An outcome score composed of only patient-derived observations may have the additional advantage of being easier to use in a routine care setting. Demonstration of a moderate level of correlation between RAPID3 and BDCAF (close to the level of weak relationship), suggests that RAPID3 likely needs more investigations before recommending its use in BS.

Entities:  

Mesh:

Year:  2013        PMID: 24064020

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  13 in total

1.  Carotid artery stiffness in Behçet's disease.

Authors:  Servet Yolbaş; Nevzat Gözel; Mustafa Necati Dağlı; Süleyman Serdar Koca; Emir Dönder
Journal:  Eur J Rheumatol       Date:  2017-06-01

2.  Venous vessel wall thickness in lower extremity is increased in male patients with Behcet's disease.

Authors:  Fatma Alibaz-Oner; Rabia Ergelen; Aydan Mutis; Zeynep Erturk; Ruslan Asadov; Gonca Mumcu; Tulin Ergun; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2019-02-13       Impact factor: 2.980

3.  Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.

Authors:  Gülen Hatemi; Alfred Mahr; Mitsuhiro Takeno; Doyoung Kim; Melike Melikoğlu; Sue Cheng; Shannon McCue; Maria Paris; Mindy Chen; Yusuf Yazici
Journal:  RMD Open       Date:  2022-07

4.  Behçet syndrome manifestations and activity in the United States versus Turkey -- a cross-sectional cohort comparison.

Authors:  Cailin Sibley; Yusuf Yazici; Koray Tascilar; Nafiz Khan; Yasmin Bata; Hasan Yazici; Raphaela Goldbach-Mansky; Gulen Hatemi
Journal:  J Rheumatol       Date:  2014-06-15       Impact factor: 4.666

5.  Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet's Disease with Intestinal Involvement and Crohn's Disease.

Authors:  Fatma Alibaz-Oner; Rabia Ergelen; Ilkay Ergenc; Gizem Seven; Ayten Yazıcı; Ayse Cefle; Cemal Bes; Ozlen Atug; Haner Direskeneli
Journal:  Dig Dis Sci       Date:  2020-09-14       Impact factor: 3.199

6.  Serum adropin level and ENHO gene expression in systemic sclerosis.

Authors:  Servet Yolbas; Murat Kara; Musa Yilmaz; Suleyman Aydin; Suleyman Serdar Koca
Journal:  Clin Rheumatol       Date:  2016-04-15       Impact factor: 2.980

7.  Possible Role of Regulatory B Cells in Different Behçet's Disease Phenotypes and Therapies: First Report from Egypt.

Authors:  Helal F Hetta; Alaa A A Mohamed; Asmaa M Zahran; Safaa A Mahran; Marwa My Sayed; Mohamed Ga Saleh; Khaled Abdelazeem; Gaber El-Saber Batiha; Salim Al-Rejaie; Yasir Waheed; Khalid Muhammad; Manal M Hassanien
Journal:  J Inflamm Res       Date:  2021-03-08

8.  Validation and reliability of a Behcet's Syndrome Activity Scale in Korea.

Authors:  Hyo Jin Choi; Mi Ryoung Seo; Hee Jung Ryu; Han Joo Baek
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884

9.  Hematological Indices May Be Useful in the Diagnosis of Systemic Lupus Erythematosus and in Determining Disease Activity in Behçet's Disease.

Authors:  Servet Yolbas; Ahmet Yildirim; Nevzat Gozel; Burak Uz; Suleyman Serdar Koca
Journal:  Med Princ Pract       Date:  2016-06-24       Impact factor: 1.927

10.  Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.

Authors:  Matheus Vieira; Solène Buffier; Mathieu Vautier; Alexandre Le Joncour; Yvan Jamilloux; Mathieu Gerfaud-Valentin; Laurence Bouillet; Estibaliz Lazaro; Stéphane Barete; Laurent Misery; Delphine Gobert; Tiphaine Goulenok; Olivier Fain; Karim Sacre; Pascal Sève; Patrice Cacoub; Cloé Comarmond; David Saadoun
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.